The Laboratory of Molecular and Tumor Immunology, led by Bernard A. Fox, Ph.D., hypothesizes that a primary reason for the failure of past tumor vaccine strategies is that the magnitude of the antitumor immune response is insufficient to mediate tumor regression. One answer to this is to create a lymphopenic host, reconstitute that host with lymphocytes and then inoculate with a tumor vaccine.
Adoptive Cellular Therapy in Melanoma
Clinical Trial of Dribble Vaccine in NSCLC (R21 CA123864 pending PI: Walter J. Urba, M.D., Ph.D.)
Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC
Exploiting lymphopenia and depletion of CD25+ regulatory T cells to augment effective immunotherapy (Prostate Cancer Foundation – PI: Bernard A. Fox, Ph.D.).
Enter your ZIP to see local news and info